Telehealth ADHD Prescribing: What PMHNPs Can Do in New York

Let’s talk about ADHD prescribing like we’re grabbing coffee after rounds – real talk about what actually matters for your practice. Whether you’re an established psychiatrist or a PMHNP just finishing your supervised hours, the landscape for managing ADHD via telehealth has gotten complicated. Federal waivers that saved us during COVID are expiring, state laws vary wildly, and meanwhile your inbox is flooded with patients who can’t find anyone to refill their Adderall.

Here’s what we’re covering: federal telehealth rules for controlled substances (yes, they’re changing again), exactly what psychiatrists versus PMHNPs can prescribe in each priority state, the real economics of patient acquisition, and how reimbursement actually works for medication management visits in 2026.

Federal Telehealth Framework for ADHD Medications

The Ryan Haight Act and COVID Waivers

Under normal circumstances, the Ryan Haight Act requires an in-person medical evaluation before any provider can prescribe Schedule II controlled substances via telemedicine. That’s federal law from 2008, designed to prevent online pill mills.

Then COVID hit. In March 2020, the DEA issued a public health emergency waiver allowing providers to prescribe stimulants through telehealth without that initial face-to-face visit – as long as the encounter met standard of care and used real-time audio-video. This flexibility was extended multiple times and currently runs through December 31, 2025 (www.axios.com).

What this means for you: As of February 2026, you can still start Adderall or Vyvanse for a new ADHD patient entirely via video visit. But here’s the catch – unless Congress or the DEA creates a permanent pathway, we’re looking at a potential cliff at the end of 2025 where you’d suddenly need in-person exams again (www.axios.com).

The DEA proposed a ‘telemedicine special registration’ rule in 2023 that would let qualified providers prescribe controlled substances via telehealth long-term, but it’s been sitting in regulatory limbo. Most of us are operating under the extended waiver and hoping for permanent legislation.

What Happens After December 2025?

Nobody knows for certain. Three possible scenarios:

1. Extension: DEA issues another temporary extension (what they’ve done three times already)
2. Permanent Rule: Congress passes legislation or DEA finalizes its special registration pathway
3. Cliff: The waiver expires and we’re back to Ryan Haight’s in-person requirement

If scenario three happens, you’d need to see new ADHD patients in person at least once before prescribing stimulants remotely. Existing patients you’ve already evaluated could continue via telehealth (the Ryan Haight Act allows ongoing telehealth for patients you’ve initially seen face-to-face).

Smart practice planning means having a backup – maybe partnering with local clinics where patients could do initial in-person visits, or limiting your telehealth ADHD practice to patients you can feasibly see once in person.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist vs PMHNP Prescribing Authority: What Actually Matters

Let’s be clear about the fundamental difference: Psychiatrists (MD/DO) have unrestricted prescriptive authority in all 50 states. If you’re licensed in a state and have your DEA registration, you can prescribe any ADHD medication without anyone looking over your shoulder.

PMHNPs? It’s complicated and state-dependent.

Full Practice Authority States

About 26 states now offer ‘Full Practice Authority’ for nurse practitioners – meaning after meeting certain requirements (usually 2-4 years supervised experience), PMHNPs can practice completely independently including prescribing Schedule II stimulants.

New York is a good example: PMHNPs need 3,600 hours (roughly two years) of supervised practice with a collaborative agreement. After that, they can practice autonomously and prescribe any medication including Adderall without physician oversight (rxagent.co).

Illinois grants FPA after 4,000 hours of collaborative practice plus 250 hours of continuing education. Once you have it, you’re independent – though Illinois still requires a consultation agreement with a physician for Schedule II narcotics (pain meds), that requirement doesn’t apply to ADHD stimulants (rxagent.co).

California is transitioning. Under AB 890, experienced NPs (3+ years, 4,600 hours) can now apply for independent status (‘104 NP’). They still need to complete a pharmacology course specific to controlled substances, but once approved, they can prescribe stimulants autonomously (rxagent.co).

Restricted Practice States

Texas and Florida remain heavily restricted – and this matters enormously for ADHD practice.

Texas NPs cannot prescribe Schedule II controlled substances for outpatient care – period. The only exceptions are hospitalized patients, emergency settings, or hospice care (rxagent.co). This means a Texas PMHNP literally cannot write an Adderall prescription for an adult ADHD patient at home, even with a supervising physician. The psychiatrist has to write it.

If you’re a PMHNP considering telehealth work in Texas: you’ll be doing therapy, patient education, and managing non-stimulant options (like atomoxetine or bupropion), but any patient needing Adderall will require an MD to handle that prescription. This creates workflow challenges but also means psychiatrists are in extremely high demand there.

Florida has a workaround. The state limits NPs to 7-day supplies of Schedule II drugs unless they’re a ‘psychiatric nurse’ working under a psychiatrist’s protocol treating mental health conditions (www.leg.state.fl.us). PMHNPs with proper certification can prescribe month-long stimulant prescriptions, but they still need that physician collaboration agreement – they’re not independent (www.leg.state.fl.us).

Pennsylvania restricts initial Schedule II prescriptions by NPs to just 72 hours, requiring physician notification. Ongoing prescriptions can be 30 days, but the physician must re-evaluate the patient before extending beyond that initial month (rxagent.co). In practice, this means PA psychiatrists often handle initial ADHD evaluations and stimulant starts, with NPs managing stable follow-ups.

Collaborative Agreements: What They Actually Mean

In restricted states, ‘collaborative agreement’ doesn’t mean the psychiatrist sees every patient or signs every prescription. It means:

• You have a written protocol outlining scope of practice
• The supervising physician is available for consultation (usually by phone/text)
• They conduct periodic chart reviews (varies by state – maybe 10% of charts quarterly)
• In some states, there are limits on how many NPs one psychiatrist can supervise (Florida: 4, Texas: 7, Pennsylvania: 4)

For ADHD specifically, the collaboration might specify: ‘NP may diagnose ADHD, order rating scales, prescribe stimulants per FDA guidelines up to [X dose], and manage side effects. Physician available for consultation on complex cases or treatment failures.’

Reality check: If you’re a PMHNP in a restricted state joining a telehealth platform, make sure they’ve arranged collaborative agreements. Some platforms handle this centrally; others expect you to find your own collaborating physician, which can be challenging remotely.

State-Specific Deep Dive: Where You Can Actually Practice

California: Progressive But In Flux

The Good: California explicitly allows telehealth prescribing of stimulants for psychiatric conditions. The state’s telehealth statute has no additional restrictions beyond federal law, and insurance parity is strong (www.flsenate.gov).

The Challenge: If you’re a newer PMHNP, you’re still in the ‘103 NP’ category requiring physician oversight until you hit 3 years experience. California’s DEA and controlled substance licensing requirements are straightforward for MDs but NPs need that extra pharmacology course before prescribing Schedule IIs (rxagent.co).

Market Reality: California has roughly 7,800 psychiatrists for 40 million people – about 1 per 5,000 residents (www.healingpsychiatryflorida.com). That sounds decent until you look at distribution – the Central Valley and Inland Empire are severely underserved. Adult ADHD demand is particularly high in tech-heavy areas (Bay Area, LA) where awareness is high and patients expect convenient care.

Reimbursement: California commercial insurance pays well – often 10-20% above Medicare rates for psychiatry. Private pay is also viable; many patients will pay $200-300 for initial evaluations. Medi-Cal (Medicaid) rates are lower but the state mandates telehealth parity.

Texas: High Demand Meets High Restrictions

Scope Reality: Only psychiatrists can prescribe outpatient stimulants. PMHNPs need MD supervision and cannot write Schedule II scripts even with collaboration (rxagent.co).

Telehealth Rules: Texas explicitly allows teleprescribing for mental health conditions via live video (not audio-only). The state prohibits telehealth prescribing for chronic pain management but ADHD doesn’t fall under that restriction (www.cchpca.org).

Market Opportunity: Texas has one of the worst psychiatrist shortages in the nation – about 1 per 9,000 residents, rank 43rd (www.healingpsychiatryflorida.com). Over 185 of 254 counties are mental health shortage areas. If you’re a Texas-licensed psychiatrist doing telehealth ADHD care, you can fill your schedule quickly.

The Catch: Texas has been scrutinizing telehealth ADHD prescribing after some high-profile cases of companies overprescribing stimulants with minimal evaluation (capitol.texas.gov). Practice defensively – document thoroughly, use rating scales, check the PDMP, and schedule regular follow-ups. The Texas Medical Board will investigate if complaints arise.

Florida: Psychiatric Exception Makes It Work

Key Law: Florida statute 456.47 explicitly permits telehealth providers to prescribe Schedule II controlled substances when treating ‘psychiatric disorders’ – ADHD qualifies (www.flsenate.gov). This is unusual and helpful.

NP Practice: PMHNPs need a psychiatrist supervisor but can prescribe month-long stimulant prescriptions if properly credentialed as a ‘psychiatric nurse’ (www.leg.state.fl.us).

Market: Florida ranks 42nd in psychiatrist supply (1 per 8,577 people) (www.healingpsychiatryflorida.com). South Florida has decent coverage but North Florida and rural areas are deserts. Large aging population plus substantial young adult population = high ADHD demand across age groups.

PDMP Compliance: Florida mandates checking EFORCSE (their prescription monitoring program) before prescribing controlled substances. This is non-negotiable and audited.

New York: Independent NPs After Dues Paid

Best Feature: After 3,600 supervised hours, PMHNPs practice completely independently with full prescriptive authority including Schedule II stimulants – no ongoing physician oversight needed (rxagent.co).

Mandatory Requirements: All prescriptions must be electronic (NY was early adopter of e-prescribing mandate). You must check the state PDMP before writing any controlled substance prescription – every single time. Failure to do this is a Board violation.

Market Dynamics: New York has the best psychiatrist-to-population ratio of our focus states (1:2,900) (www.healingpsychiatryflorida.com), heavily concentrated in NYC. This means competition in the city but opportunity upstate. Rural counties still struggle to find providers.

Reimbursement: NY commercial insurance pays among the highest rates in the country for psychiatry (reflecting cost of living). Medicaid rates are lower but the state requires parity for telehealth. Many NYC patients have coverage or can pay cash.

Pennsylvania: Procedural Hurdles

NP Limitations: The 72-hour initial prescription limit for Schedule IIs creates workflow issues. A PMHNP can start a patient on stimulants but only for 3 days, requiring physician involvement for continuation (rxagent.co).

Practical Workaround: Many PA practices have the psychiatrist do initial ADHD evaluations and write the first month of medication, then transition stable patients to PMHNP for ongoing monthly follow-ups (which the NP can prescribe for 30 days).

Supply: PA has moderate psychiatrist density (1 per ~4,600 residents) – better than many states but still with significant rural shortages (www.healingpsychiatryflorida.com). Philadelphia and Pittsburgh are well-covered; central and northern PA not so much.

Illinois: Transition to Independence

NP Path: After 4,000 hours of collaborative practice plus continuing education, PMHNPs can obtain Full Practice Authority and prescribe independently including stimulants (rxagent.co).

Current Reality: By 2026, many experienced PMHNPs in Illinois have obtained FPA. Newer NPs still need collaborative agreements, but the state is increasingly NP-friendly.

Market: Illinois ranks 18th in psychiatrist density (1 per ~5,800) – Chicago is well-supplied but downstate areas face shortages (www.healingpsychiatryflorida.com). Telehealth particularly valuable for reaching rural southern Illinois.

Recent Change: Illinois mandated e-prescribing for all controlled substances starting January 2023, aligning with federal Medicare requirements. All providers need EPCS capability.

The Real Economics: Patient Acquisition vs Platform Models

Let’s talk money – specifically, what it actually costs to acquire and treat ADHD patients, because this is where a lot of provider content gets it wrong.

The DIY Marketing Myth

You’ll see articles claiming you can acquire psychiatric patients for ‘$30-50 through Facebook ads’ or ‘build an SEO practice for pennies.’ This is fiction for ADHD specifically.

Reality of DIY Patient Acquisition:

• SEO Investment: Takes 6-12 months of consistent content creation, technical optimization, and link building before generating meaningful organic traffic. You’re looking at $2,000-4,000/month if hiring an agency, or 20+ hours/week of your own time. Even then, local ADHD searches are dominated by established practices and Psychology Today profiles.

• Google Ads: Mental health keywords are expensive. ‘ADHD psychiatrist near me’ runs $15-40 per click in major metros. Your conversion rate from click to booked appointment might be 5-10% (most clicks are tire-kickers, wrong insurance, or no-shows). Realistic cost per booked patient: $200-400+.

• Directory Listings: Psychology Today charges $30/month for a basic listing where you compete with 200+ other providers in the same zip code. Zocdoc takes $35-100+ per booking plus monthly subscription fees. These costs add up fast.

• Total Reality: Once you factor in all marketing spend, failed campaigns, staff time handling leads and coordinating insurance verification, no-show rates from cold leads, and opportunity cost – acquiring a qualified psychiatric patient through DIY marketing costs $200-500+ on average.

And that’s just to get them in the door once. You still need to verify insurance, get prior authorizations for medications, manage scheduling, handle billing, etc.

The Platform Model Economics

This is where the Klarity Health model makes business sense – and why being honest about economics matters.

How it works: You pay a standard fee per new patient appointment (similar to Zocdoc’s per-booking model, but specifically for psychiatric care). That fee covers:

• Pre-qualified patient matching based on your specialty and availability
• Insurance verification already done
• Built-in telehealth platform (no separate EMR subscription needed)
• EPCS capability for controlled substances
• Billing infrastructure for both insurance and cash pay
• No monthly subscription fees or upfront marketing spend

The Value Proposition: Instead of spending $3,000-5,000/month on marketing with uncertain results and 6-12 month lag time, you pay only when a qualified patient actually books with you. It’s guaranteed ROI vs. gambling on marketing channels you may not have expertise in.

Example Math:

• Traditional route: $4,000/month marketing + 20 hours/week of your time managing it = $10,000+ monthly cost for maybe 15-20 new patients (if you’re good at marketing)
• Platform route: Pay per appointment × number of patients you want to see = predictable cost structure, zero risk months, fill your schedule as fast or slow as you want

For most providers, especially those building a practice or scaling up, removing all patient acquisition risk is worth the per-appointment fee.

Important: No Unrealistic CAC Claims

We’re not going to quote you a ‘$30 patient acquisition cost’ because it’s not real for psychiatric care. Quality ADHD patients – who show up, have appropriate insurance or can pay, and need ongoing medication management – cost money to acquire through any channel.

What matters is predictability and risk. DIY marketing might eventually be cost-effective if you have the expertise, patience, and budget to invest for 6-12 months with no immediate return. A platform that handles acquisition removes that risk entirely.

Reimbursement Reality: What You’ll Actually Get Paid

Let’s talk real numbers for medication management visits in 2026.

Medicare Rates (Baseline)

Medicare sets the floor for reimbursement. For ADHD medication management visits, you’ll typically bill:

• 99213 (15-minute established patient visit, low complexity): ~$89-95 (therathink.com)
• 99214 (25-minute established patient visit, moderate complexity): ~$125-136 (therathink.com)
• 90792 (Initial psychiatric evaluation with medical services): ~$188-202 (therathink.com)

These rates apply to telehealth exactly the same as in-person – Medicare has maintained payment parity for mental health telehealth services (www.kiplinger.com).

Commercial Insurance

Private insurers generally pay 10-30% above Medicare rates, sometimes more in high-cost areas:

• Blue Cross/Blue Shield plans: Typically 110-120% of Medicare
• United Healthcare, Aetna: Similar range
• Regional plans: Varies widely; some pay 140-150% of Medicare in expensive metros

A typical 15-minute ADHD med check might reimburse $100-130 from commercial insurance; a 25-minute visit $140-180.

Medicaid: The Reality Check

Medicaid pays roughly 40-60% of Medicare rates in most states. Example rates:

• 99213: ~$40-65 (therathink.com)
• 99214: ~$64-90

This is why many psychiatrists don’t take Medicaid despite the need – you’d need to see twice as many patients to match commercial insurance revenue. Telehealth platforms can help make Medicaid viable by eliminating overhead and increasing efficiency.

Telehealth Parity Status

Nearly 48 states now have some form of telehealth payment parity – meaning insurers must reimburse telehealth visits the same as in-person (behavehealth.com).

Key points:

• Medicare: Payment parity mandatory through at least 2024, extensions likely
• Commercial: Most states mandate parity by law or insurers voluntarily comply
• Medicaid: Most state Medicaid programs now reimburse telehealth at parity

This means you’re not taking a pay cut by practicing virtually.

Psychiatrist vs NP Reimbursement

Psychiatrists (MD/DO) typically receive full reimbursement rates. PMHNPs billing under their own NPI receive 85% of the physician rate under Medicare (private insurers vary).

Example:

• Psychiatrist bills 99214 → receives $125 from Medicare
• PMHNP bills same code → receives ~$106 (85% of $125)

Some practices have NPs bill ‘incident to’ the supervising physician to get full rates, but this requires specific billing conditions (physician must be available, among other requirements) that often don’t apply in telehealth settings.

Bottom line: Psychiatrists command slightly higher reimbursement, which partially explains why they’re in such demand for ADHD care.

Realistic Revenue Modeling

Scenario: Part-time telehealth ADHD practice (15 hours/week clinical time)

Assume mostly established patients (monthly follow-ups) with a few new evaluations:

• 12 med checks per week (15 min each) @ $110 average = $1,320
• 2 initial evaluations per week @ $190 = $380
• Weekly revenue: $1,700
• Monthly revenue (4 weeks): $6,800

That’s gross before platform fees, but after subtracting those, you’re likely netting $4,500-5,500/month for 60 hours of work – roughly $75-90/hour net. Competitive with employed positions but with complete schedule flexibility.

Scale that to full-time (40 hours clinical) and you’re looking at $150K+ annual income from telehealth ADHD practice.

ADHD Medication Shortages: The Reality Nobody Talks About

Since late 2022, ADHD medication shortages have been a persistent problem – and they directly impact your practice.

What Happened

Prescriptions for ADHD medications surged during the pandemic. Adults sought diagnosis and treatment in record numbers as telehealth made care accessible (apnews.com). This increase, combined with DEA manufacturing quotas and supply chain issues, created widespread shortages of Adderall and other stimulants (www.axios.com).

Current Status (2026)

The situation has improved somewhat – the DEA raised production quotas in response to the shortage – but intermittent supply issues persist. Patients frequently report:

• Generic amphetamine salts unavailable at their pharmacy
• Brand name Adderall or Vyvanse on backorder
• Having to call multiple pharmacies to find filled prescriptions

How This Affects Your Practice

Patient frustration: You’ll field calls about medication unavailability. This isn’t your fault, but it creates extra workload.

Treatment adaptation: Be prepared to:

• Switch between stimulant formulations (methylphenidate if amphetamine unavailable, or vice versa)
• Use alternative dosing strategies (different immediate-release options)
• Consider non-stimulant options (atomoxetine, bupropion, guanfacine) as backups
• Guide patients to pharmacies with better supply (often independent pharmacies vs chains)

Documentation: Note in your records when shortages force medication changes – this protects you if insurance questions why you switched a stable patient’s prescription.

Why Shortages Will Continue

The DEA sets annual manufacturing quotas for controlled substances. Even when they increase limits, it takes months for manufacturers to ramp up production. As long as demand remains high (and it will – adult ADHD awareness isn’t going away), we’re likely to see ongoing supply/demand imbalances.

Practice tip: Build relationships with a few local pharmacies and know which ones tend to have better stimulant supply. When starting patients on stimulants, ask which pharmacy they use and have a backup plan.

Clinical Workflow for Telehealth ADHD Care

Here’s what a compliant, defensible ADHD telehealth practice looks like:

Initial Evaluation (45-60 minutes)

Required elements:

• Comprehensive psychiatric history (childhood symptoms, school performance, work history)
• DSM-5 diagnostic criteria assessment (6+ symptoms of inattention and/or hyperactivity-impulsivity, present before age 12, impairing function in multiple settings)
• Rating scales: Adult ADHD Self-Report Scale (ASRS) or similar validated tool
• Rule out differentials (anxiety, depression, substance use, learning disabilities)
• Medical history: cardiovascular screening (stimulants can increase BP and heart rate)
• Collateral information when possible (especially for kids – teacher reports, parent interviews)

Risk assessment:

• History of substance misuse (stimulants have abuse potential)
• Diversion risk factors (requests for early refills, ‘lost’ prescriptions)
• Cardiac history (stimulants contraindicated in some conditions)

Documentation must include:

• Patient location (for licensure compliance)
• Verbal consent for telehealth treatment
• That visit met standard of care for telemedicine
• PDMP check results (note date and what you found)

Prescribing decision: If starting a stimulant, document rationale. Consider starting with a lower dose and titrating up rather than jumping to maximum doses immediately.

Follow-Up Visits (15-20 minutes monthly)

ADHD medication management typically requires monthly visits since most stimulants are prescribed in 30-day supplies (Schedule II drugs cannot be called in or refilled – each month requires a new prescription).

Monthly check should cover:

• Efficacy: Are symptoms controlled? (Use rating scales periodically to quantify)
• Side effects: Sleep, appetite, anxiety, heart rate/BP if available
• Adherence: Missing doses? Taking as prescribed?
• Functioning: Work/school performance, relationships improving?
• Diversion screening: Any red flags (early refill requests, vague stories about lost meds)

PDMP checks: Most states require checking at least every 90 days for ongoing controlled substance prescribing. Some providers check monthly. Document when you check.

E-prescribing: Most states now mandate electronic prescribing for controlled substances. Your platform needs EPCS capability (two-factor authentication required by federal law).

Handling Complex Cases

When to refer or get consultation:

• Comorbid bipolar disorder (stimulants can precipitate mania)
• Active substance use disorder
• Unclear diagnosis (symptoms may be from trauma, autism, etc.)
• Treatment failure after trials of multiple medications
• Pediatric cases requiring school accommodation coordination

Not every ADHD patient is appropriate for telehealth med management. Setting boundaries protects both you and patients.

Compliance and Risk Management

Let’s be blunt: ADHD prescribing via telehealth has gotten regulatory attention because of bad actors. A few companies were investigated for inappropriate prescribing of stimulants with minimal evaluation (capitol.texas.gov). Don’t be one of them.

Best Practices to Stay Safe

1. Thorough EvaluationsDocument comprehensively. If a Board investigates, your notes need to show you met standard of care – not ’15-minute video chat, started Adderall 20mg.’

2. Rating ScalesUse validated tools (ASRS, Conners, etc.). Quantitative data supports your diagnosis and treatment decisions.

3. PDMP ChecksCheck every time in states that mandate it; best practice is to check regularly even if not required. Document what you found (or that you found no concerning patterns).

4. Red Flags for DiversionBe alert to:

• Requests for specific doses/’my friend takes XYZ dose’
• Early refill requests with dubious explanations
• Lost or stolen medication reports (once might be legitimate; repeatedly is a red flag)
• Resistance to trying non-stimulant alternatives
• Cash-only patients who avoid insurance (could indicate doctor shopping)

5. Coordination with Primary CareEspecially for patients with cardiac risk factors, coordinate vitals monitoring. You might ask patients to get BP checked at their P

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the